Application of targeted MIF in preparation of medicine for treating atopic dermatitis

Through the small molecule inhibitor ISO-1, a small molecule inhibitor targeting MIF, the problem of difficulty in effectively treating the inflammation and immune response caused by atopic dermatitis, especially house dust mite allergic, is solved, and demonstrates its significance in the HDM allergic mouse model. The therapeutic effect reduces skin inflammation and itching and provides new therapeutic targets.

CN119074725AActive Publication Date: 2024-12-06PEKING UNIVERSITY FIRST HOSPITAL (PEKING UNIVERSITY FIRST CLINICAL MEDICAL COLLEGE)
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411268684.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-12-06
Estimated Expiration
2044-09-11

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat atopic dermatitis, especially the inflammation and immune response caused by house dust mite allergies, and the role of existing treatments on MIF in the development of the disease has not been fully utilized.

Method used

Using the small molecule inhibitor ISO-1, which targets MIF, as a drug, the activity of MIF is inhibited to alleviate the symptoms of atopic dermatitis through the form of an intraperitoneal injection, especially in the HDM allergic mouse model.

Benefits of technology

The MIF antagonist ISO-1 significantly improved the symptoms of dermatitis caused by house dust mites, reduced skin inflammation and itch, inhibited the expression of Th2-related cytokines, and provided a new target for the treatment of atopic dermatitis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005037991790000011
    Figure HDA0005037991790000011
  • Figure HDA0005037991790000012
    Figure HDA0005037991790000012
  • Figure HDA0005037991790000013
    Figure HDA0005037991790000013
Patent Text Reader

Abstract

On one hand, the invention discloses application of targeted MIF in preparation of a medicine for treating atopic dermatitis, and on the other hand, the invention discloses a medicine for targeted treatment of atopic dermatitis. The medicine for treating atopic dermatitis is an MIF small molecule inhibitor. The MIF small-molecule inhibitor is an MIF antagonist ISO-1 (International Standardization Organism 1). The research on the treatment effect of the phage migration inhibition factor MIF in the HDM anaphylactic mouse AD model proves that the MIF has a good treatment effect in the HDM anaphylactic mouse AD model.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to an application of a targeted macrophage migration inhibitory factor (MIF) in the preparation of a drug for treating atopic dermatitis and a drug for the targeted treatment of atopic dermatitis. Background Art

[0002] Atopic dermatitis (AD) is a recurrent, pruritic, inflammatory skin disease that is considered the first step in the atopic process. Many AD patients have increased reactivity to aeroallergens and food allergens. House dust mites (HDM) are the most common aeroallergens and are considered an important factor in inducing and aggravating AD. The level of HDM-specific IgE in the serum of AD patients is increased and positively correlated with the severity of the disease; HDM desensitization therapy can effectively improve the clinical symptoms of AD. In addition, HDM also stimulates keratinocytes in AD patients to release Th2-related cytokines, such as interleukin-(IL-)25 and IL-33, thereby aggravating the immune response.

[0003] Macrophage migration inhibitory factor (MIF) plays the role of pleiotropic cytokine by participating in the inflammatory and immune response processes, thus contributing to the immune regulation and occurrence and development of allergic diseases. Summary of the invention

[0004] The purpose of the present invention is to provide a targeted macrophage migration inhibitory factor MIF for use in the preparation of a drug for treating atopic dermatitis and a drug for targeted treatment of atopic dermatitis.

[0005] According to a first aspect of the present invention, a method for targeting MIF is used in the preparation of a drug for treating atopic dermatitis, wherein the drug for treating atopic dermatitis is a MIF small molecule inhibitor.

[0006] Preferably, the MIF small molecule inhibitor is an injection.

[0007] Preferably, the MIF small molecule inhibitor is an intraperitoneal injection.

[0008] Preferably, the MIF small molecule inhibitor is the MIF antagonist ISO-1.

[0009] Preferably, the injection dose of the MIF antagonist ISO-1 is 35 mg×(±10%) / kg.

[0010] According to a second aspect of the present invention, a drug for targeted treatment of atopic dermatitis is provided, wherein the drug for treating the atopic dermatitis is a MIF small molecule inhibitor.

[0011] Preferably, the MIF small molecule inhibitor is an injection.

[0012] Preferably, the MIF small molecule inhibitor is an intraperitoneal injection.

[0013] Preferably, the MIF small molecule inhibitor is the MIF antagonist ISO-1.

[0014] Preferably, the injection dose of the MIF antagonist ISO-1 is 35 mg×(±10%) / kg.

[0015] The present invention studies the therapeutic effect of macrophage migration inhibitory factor MIF in the HDM allergic mouse AD model, and confirms that MIF has a good therapeutic effect in the HDM allergic mouse AD model. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 Schematic diagram of the induction scheme of the HDM-sensitized AD mouse model;

[0017] Figure 2 Schematic diagram of ISO-1 treatment regimen in HDM-sensitized AD mouse model;

[0018] Figure 3 Schematic diagram of the manifestations of the HDM-induced mouse AD model and the therapeutic effect of the MIF antagonist ISO-1 in this model;

[0019] Figure 4 Schematic diagram of the results of immunofluorescence and RT-PCR of MIF in mouse skin;

[0020] Figure 5 Schematic diagram of changes in macrophage activation indicators. DETAILED DESCRIPTION

[0021] The present invention provides an application of targeted MIF in the preparation of a drug for treating atopic dermatitis, wherein the drug for treating atopic dermatitis is a MIF small molecule inhibitor.

[0022] The present invention also provides a drug for the targeted treatment of atopic dermatitis, wherein the drug for treating the atopic dermatitis is a MIF small molecule inhibitor.

[0023] The above-mentioned MIF small molecule inhibitor is an injection. In particular, the above-mentioned MIF small molecule inhibitor is an intraperitoneal injection.

[0024] Specifically, the MIF small molecule inhibitor is the MIF antagonist ISO-1. The injection dose of the MIF antagonist ISO-1 is 35 mg×(±10%) / kg.

[0025] The test method, test steps, test process control conditions and test results of the present invention

[0026] Construction of HDM-induced AD mouse model:

[0027] This study used adult male (8-10 weeks old) C57BL / 6J wild-type (purchased from Beijing Sibeifu Company) mice, and the mice were free to eat and drink water under specific pathogen-free conditions of 23°C, 12:12 day and night cycle and 50±10% humidity. All experimental procedures were approved by the Animal Ethics Committee of Peking University First Hospital. To induce the HDM-allergic AD mouse model, calcipotriol (MC903; 6nmol / 60μl; Tocris Bioscience, UK) dissolved in ethanol was topically applied to the shaved area of ​​the mouse neck (2.5cm*2.5cm) every day for 7 days. Then, 100mg HDM ointment (Biostir AD, Japan) was applied to the same site after MC903 application, 3 times a week. After 6 HDM stimulations, the mice were euthanized and dorsal skin specimens were collected for analysis, see. Figure 1 .

[0028] ISO-1 treatment of HDM-induced AD mouse model protocol:

[0029] MC903 was applied topically to the shaved area of ​​the mouse neck skin (2.5 cm*2.5 cm) once a day for the first week. HDM ointment was applied every other day after MC903 application for a total of 6 times. ISO-1 (35 mg / kg) was injected intraperitoneally every other day throughout the modeling process.

[0030] Assessment of the severity of pruritus: Place the mice in a transparent observation box and record the video for 60 minutes. Each time the mouse raises its hind legs to scratch the skin behind the ears and neck, it is counted as one time. The number of scratches within 60 minutes is observed and recorded; AD severity index (clinical score): The intensity of skin erythema, bleeding, exudation and desquamation is assessed based on gross photos of the mouse skin. Each sign has 4 levels: 0, none; 1, mild; 2, moderate; 3, severe. The final score is the sum of the scores of the four signs. This indicator is evaluated weekly throughout the experiment, see Figure 2 .

[0031] Immunofluorescence staining:

[0032] Mouse back skin tissue sections were dewaxed, hydrated, and antigen retrieved. They were then permeabilized with 0.2% Triton X100 at room temperature for 10 minutes, blocked with 0.5% BSA at room temperature for 30 minutes, and incubated with anti-MIF antibody (1:100, Cell Signaling Technology) at 4°C overnight. TMThe sections were incubated with 488 goat anti-rabbit IgG (1:200, Invitrogen) for 2 hours at room temperature, counterstained with DAPI, and then mounted and observed and photographed under a confocal microscope (Leica).

[0033] Quantitative real-time polymerase chain reaction (qRT-PCR)

[0034] After total RNA was extracted using TRIzol (Invitrogen, CA, USA), the One-Step gDNA Removal and cDNA Synthesis SuperMix Kit reverse transcribed it into cDNA. Then qRT-PCR was performed. The total volume was 20uL, including 10uL PowerUp SYBR Green (Applied Biosystems, USA), 1uL forward substrate, 1uL reverse primer and 2uL cDNA. After cycling at 95°C for 30 seconds, 95°C was run for 5 seconds, 58-65°C was run for 34 seconds, and the cycle was repeated 40 times. Relative expression used GAPDH as an internal reference.

[0035] The present invention constructs AD animals and cell models with dust mite sensitization, and clarifies that the increased expression of MIF in keratinocytes mediated by dust mite stimulation plays an important role in the occurrence and development of atopic dermatitis in mice. MIF small molecule inhibitors have good therapeutic effects in the HDM allergic mouse AD model, providing new potential targets for drug development and clinical diagnosis and treatment of exogenous allergic AD.

[0036] The present invention has the following characteristics:

[0037] 1) HDM stimulated mice to develop AD phenotype, and the MIF antagonist ISO-1 significantly improved HDM-allergic AD symptoms.

[0038] HDM-derived allergens are one of the important pathogenic factors in the development of AD. In order to simulate the skin barrier dysfunction of AD patients and make it easier for external allergens such as HDM proteins to enter the skin, we used MC903 as an inducer to establish a HDM-allergic AD model in C57BL / 6J mice. Compared with the control group, the skin of the HDM group showed severe redness, swelling, and exudation. Histopathological staining showed that the epidermal thickness of the HDM group was significantly increased, and inflammatory cells infiltrated the dermis. In addition, the number of scratching times of HDM-allergic AD mice increased significantly ( Figure 3 ).

[0039] Immunofluorescence results showed that compared with the control group, the expression of MIF in the skin of HDM-induced AD mice was increased, mainly in the basal layer of the epidermis; qRT-PCR results showed that the relative expression of MIF mRNA in the skin of model mice was significantly increased compared with the control group ( Figure 4 ).

[0040] To evaluate the therapeutic effect of MIF antagonist ISO-1 on HDM-allergic AD, we established a mouse model using MC903 and HDM, and ISO-1 (35 mg / kg) was intraperitoneally injected every other day as described above. After ISO-1 treatment, the erythema, swelling, and exudation of the mouse skin were significantly reduced, and H&E staining showed that ISO-1 significantly inhibited epidermal hyperkeratosis and dermal inflammatory cell infiltration. Compared with the HDM group, ISO-1 significantly improved itching. In addition, after ISO-1 treatment, the expression of type 2 inflammatory-related cytokines (such as IL-4, IL-13, IL-33, and TSLP) in the lesions was significantly reduced ( Figure 3 ).

[0041] 2) MIF stimulates mouse macrophage activation, which can be inhibited by ISO-1.

[0042] In addition, MIF stimulated the activation of mouse macrophage cell line Raw264.7 cells and increased the mRNA expression of inflammatory cytokines such as IL1B, IL6, and IL10, which could be inhibited by ISO-1. Therefore, we believe that MIF induces macrophage activation, and its antagonist ISO-1 can alleviate HDM-induced allergic AD symptoms and regulate the function of macrophages ( Figure 5 ).

[0043] Although the present invention is described in detail above, the present invention is not limited thereto, and those skilled in the art can make various modifications based on the principles of the present invention. Therefore, all modifications made based on the principles of the present invention should be understood to fall within the protection scope of the present invention.

Claims

1. A method for preparing a drug for treating atopic dermatitis by targeting MIF, characterized in that: The drug for treating atopic dermatitis is a small molecule MIF inhibitor.

2. The targeted MIF according to claim 1 is used in the preparation of a medicament for treating atopic dermatitis, characterized in that: The MIF small molecule inhibitor is an injection.

3. The targeted MIF according to claim 2 is used in the preparation of a medicament for treating atopic dermatitis, characterized in that: The MIF small molecule inhibitor is an intraperitoneal injection.

4. Use of the targeted MIF according to claim 2 or 3 in the preparation of a medicament for treating atopic dermatitis, characterized in that: The MIF small molecule inhibitor is the MIF antagonist ISO-1.

5. Use of the targeted MIF according to claim 2, 3 or 4 in the preparation of a medicament for treating atopic dermatitis, characterized in that: The injection dose of MIF antagonist ISO-1 was 35 mg×(±10%) / kg.

6. A drug for targeted treatment of atopic dermatitis, characterized in that: The drug for treating the atopic dermatitis is a MIF small molecule inhibitor.

7. The drug for targeted treatment of atopic dermatitis according to claim 6, characterized in that: The MIF small molecule inhibitor is an injection.

8. The drug for targeted treatment of atopic dermatitis according to claim 7, characterized in that: The MIF small molecule inhibitor is an intraperitoneal injection.

9. The drug for targeted treatment of atopic dermatitis according to claim 7 or 8, characterized in that: The MIF small molecule inhibitor is the MIF antagonist ISO-1.

10. The drug for targeted treatment of atopic dermatitis according to claim 7, 8 or 9, characterized in that: The injection dose of MIF antagonist ISO-1 was 35 mg×(±10%) / kg.

Citation Information

Patent Citations

  • Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

    CN1523989A

  • MIF inhibitors and methods of use thereof

    US20190224274A1

  • Use of MIF and RIPK1 in perioperative ischemic brain injuries

    WO2023222051A1